Born 1969. Chairman of the Board since 2021.
Education: M.Sc. in Business and Auditing, MBA, Executive Board Program (CBS) and Executive Breakthrough Program (Egon Zehnder)
Experience: Martin Olin has held executive positions as CEO, CFO or Director in international life science companies including Novo Nordisk and Symphogen A/S and has over the years held numerous board assignments in the Nordics as well as international enterprises. Most recently, Martin Olin was CEO of Nordic Eye Venture Capital.
Current assignments: Olin is chairman of the board at DanGroup Alarm and RSP Systems and board member of Cessatech A/S (publ.) and AirHelp Inc.
Prior assignments the last five years: CEO and board member of Symphogen A/S and board member of Ascendis A/S (publ.).
Shares held in AcouSort: –
Martin Olin is independent in relation to the Company, executive officers and major shareholders.
Born 1971. Chairman of the Board since 2015.
Education: M.Sc. in Business and Administration and MBA
Experience: Linde has a vast industry experience in company development and has been CEO for Arc Aroma Pure AB, Atria Retail and Aqilles Invest AB. He has had board assignments in Optifreeze AB, Joblink Norden AB and Semenco AB.
Current assignments: Linde is the external CEO of AegirBio AB and chairman of the board at LifeAssays AB (publ), Biofrigas Sweden AB (publ), SensoDetect Aktiebolag, OptiFreeze AB, Thyrolytics AB, Stora Södergatans Fastigheter AB and Staffansgården i Trää AB. Furthermore, he is a board member of Carbiotix AB (publ), OptiFreeze Värdepapper AB, Lundatriangeln AB and Spirifer Fastigheter Aktiebolag and deputy board member of Semenco AB, Cederlinden AB, Green touch AB, Magnusgården AB and Selenozyme AB.
Prior assignments the last five years: Chairman of the Board at AcouSort AB. External CEO of Arc Aroma Pure AB and SensoDetect Aktiebolag, CEO and board member of Nordic Food Group AB, deputy board member and chairman of the board of AegirBio AB, and board member of Örneborgs Delikatesser AB, Trensums Food AB, Olle Svenssons Partiaffär AB, Lundatriangeln AB, Danji Holding AB and Danji AB.
Shares held in AcouSort: 295 400 via company
Martin Linde is independent in relation to the Company, executive officers and major shareholders.
Born 1961. Board member since 2011.
Education: M.Sc. in Electrical Engineering and Doctor of Technology at Lund Univeristy
Experience: Laurell is an elected member of the Royal Swedish Academy of Sciences since 2010, the Royal Swedish Academy of Engineering Sciences since 2007 and the Royal Physiographic Society in Lund since 2007. Laurell is a world leading researcher within microchip-based acoustophoresis and has contributed to over 200 published articles and 31 patent applications. Laurell also has many years of experience in starting and running companies and board experience from both listed and private companies, such as Genovis AB and ErySave AB. In addition to his academic and commercial experience, Professor Laurell has been awarded several awards within science, innovation and entrepreneurship. The research headed by Professor Laurell is the basis of AcouSort’s business.
Current assignments: board member of Scandi Candy AB, Scandi
Fastighets AB, Aktiebolaget Brygghuset Finn (publ), TÅLA Invest AB
and Sweden Medtech4Health AB.
Prior assignments the last five years: board member of Treat4Life AB, ISET AB and Picology Aktiebolag.
Shares held in AcouSort: 1 077 300
Thomas Laurell is independent in relation to the Company, executive officers and major shareholders.
Born 1962. Board member since 2012.
Education: Medical degree (MD) and Doctoral degree (Dr. med.) in Internal Medicine.
Experience: Scheding is Professor and research group leader at the Division of Molecular Hematology and Lund Stem Cell Center at Lunds universitet. Scheding is also Senior Consultant at the Department of Hematology at Skåne University Hospital in Lund. The main focus of Scheding’s research is stem cell biology and the development of new cell therapies in stem cell transplantations. Scheding is a member of several national and international hematology and cell therapy research councils and has contributed to over 90 published articles within his areas of research.
Current assignments: –
Prior assignments the last five years: –
Shares held in AcouSort: 881 500
Stefan Scheding is independent in relation to the Company, executive officers and major shareholders.